Vanguard Global Advisers’s Avita Medical RCEL Stock Holding History

Vanguard Global Advisers’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.2K	Hold	9,734	–	–	﹤0.01%	3139
2026 Q1	$36K	Buy	+9,734	New	+$40.9K	﹤0.01%	3139

Other funds holding RCEL

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's RCEL Position: Q2 2026 in Review

Vanguard Global Advisers held its Avita Medical (RCEL) position steady in Q2 2026 at 9,734 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3139.

Vanguard Global Advisers first reported a position in RCEL in Q1 2026 and has held it in 2 quarters since. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

Vanguard Global Advisers held 9,734 shares of Avita Medical worth $40.2K as of Q2 2026.
Vanguard Global Advisers left its Avita Medical share count unchanged in Q2 2026.
Avita Medical made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3139 holding.
Vanguard Global Advisers first reported a position in Avita Medical in Q1 2026 and has held it in 2 quarters since.
73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.